INCY Stock — Incyte Corp

Up next

Next earnings call

Feb 9, 2027 Est · unconfirmed · in 12 wks

Q3 2026 earnings call transcript

call held Oct 29, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 13

Current report 8-K

Other events

Oct 29

Earnings call

Q3 2026 earnings call

Incyte Corp reported third-quarter revenue of $1.56 billion and net sales of $1.32 billion, both up 14%, and raised full-year total net sales guidance to $5,210 million to $5,300 million. Its pipeline includes six Phase III assets.

Oct 29

Quarterly report 10-Q FY2026 Q3, ended Sep 30

FDA approves JAKAFI XR extended release tablets

Incyte reported that the FDA approved JAKAFI XR extended release tablets in May 2026.

Revenue $1.56B ▲ 14.0% Net loss $784.8M Diluted EPS -$3.86

Read from the MD&A section

2 source passages

Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. In May 2026, the FDA approved JAKAFI XR (ruxolitinib) extended release tablets Open the document at this passage

Oct 29

Current report 8-K

Financial results

Incyte reported third-quarter 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, each increased 14%, and raised full-year 2026 total net sales guidance to $5,210 - $5,300 million.

Sep 9

Investor event

21st Annual Wells Fargo Healthcare Conference AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$6.01B

Trailing 12 months

Net income (TTM)

$403.41M

Trailing 12 months

Revenue growth YoY

+14.0%

Year over year

Operating margin

10.4%

Trailing 12 months

P / E (TTM)

64.3

Trailing earnings · reciprocal yield 1.6%

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.9%

Year over year · more shares

Price change (1Y)

+14.8%

Trailing year

Short interest

5.2%

Latest settlement · 5.6 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▲16.3% $1.18B $201.21M '24 Q4* ▲19.5% $1.05B $158.20M '25 Q1 ▲16.5% $1.22B $405.00M '25 Q2 ▲20% $1.37B $424.17M '25 Q3 ▲27.8% $1.51B $299.28M '25 Q4* ▲20.9% $1.27B $303.33M '26 Q1 ▲37.7% $1.67B $585.61M '26 Q2 LATEST ▲14% $1.56B −$784.80M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +11%

above

Price vs 50-day avg +2%

above

RSI (14) 54

neutral

MACD trend Positive

52-week position 77%

mid-range

Momentum

relative strength

Very Strong

1-month return +7%

trailing

6-month return +25%

trailing

YTD return +22%

this year

Relative strength +24%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $119 › 200d $109 — 50d above 200d

Institutional flow Distributing

820 of 869 funds reported for Sep 30 · net -1.5M sh shares · +115 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.22% of shares out · ▲ +6.2% MoM · 5.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

869 holders — near 3-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Excellent

Revenue growth +14%

Y/Y

EPS growth +4173%

Y/Y

Valuation P/E 64.4

in line

Buyback $4.0B

authorized

Balance sheet $3.1B

net cash

Quant / Vol

risk profile

Moderate

Volatility 33%

annualized · 1-yr

Max drawdown −18%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Oct 29, 2026

Total net sales · full year 2026 Raised $5.21B – $5.3B

Jul 28, 2026 $5.13B – $5.26B Oct 29, 2026 $5.21B – $5.3B

prior FY $5.14B midpoint +2.2% Y/Y

Opzelura net sales · full year 2026 Raised $1.1B – $1.12B

Jul 28, 2026 $1.05B – $1.1B Oct 29, 2026 $1.1B – $1.12B

Hematology and Oncology net sales · full year 2026 Raised $890M – $910M

Jul 28, 2026 $860M – $890M Oct 29, 2026 $890M – $910M

Previous outlook earlier release · from the 8-K filed Apr 28, 2026

Still-open targets the latest release did not restate under the same label.

Jakafi net sales · fiscal year 2026 $3.22B – $3.27B

Guided vs delivered · last 1 settled

Full year 2025 net product revenue full year 2025

guided $4.23B – $4.32B

guided $4.23B – $4.32B $5.14B Beat +20.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+11% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

54 Neutral

MACD trend

Positive Bullish

52-week position

77% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $119 › 200d $109 — 50d above 200d

Institutional flow Distributing

820 of 869 funds reported for Sep 30 · net -1.5M sh shares · +115 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.22% of shares out · ▲ +6.2% MoM · 5.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

869 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $90 Now $121 · 77% Range high $130

vs 200-day avg +11% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INCY Incyte Corp this stock	$24.66B	+22.5%	+13.7%	64.4	5.2%
VRTX Vertex Pharmaceuticals Inc	$136.56B	+18.8%	+46.2%	34.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$98.84B	+23.8%	+20.8%	21.1	2.1%
MRNA Moderna, Inc.	$90.38B	+657.4%	+4.3%	—	8.2%
CSLLY Csl Ltd	$66.05B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

928

% held: 99.2%
Reported: 820 of 869
Top holder: BAKER BROS. ADVISORS LP

Held Float

View

Held by Funds

Fund positions

843

View

Short & Settlement

Short Interest Rising

Shares short

10.6M

Days to cover: 5.6d
Change: +624.0K sh

View

Short Volume

Short vol %

61%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

6

Value: $652
As of: Oct 14, 2026

View

Off-Exchange

Off-exchange %

45.9%

Week of: Oct 5, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Rob Bresnahan

Amount: $1.0K–$15.0K
Traded: May 15, 2025

View

Financials

Revenue (FY)

$5.1B

Net income (FY): $1.3B
EPS diluted: $6.41

View

Buybacks

Authorized · 3 programs

$4.0B

View

Filings

SEC Filings

Latest

8-K

Filed: Nov 13, 2026
This year: 25

View

Proposed Sales

Value

$1.3M

Shares: 10.7K
Filed: Nov 13, 2026

View

Earnings & Events

Webcasts

Last webcast

Oct 29, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
INCY	+1.1%	+7.0%	+24.6%	+0.5%	+22.5%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-1.5%	+8.2%	+24.1%	+0.7%	+11.9%

INCY · Incyte Corp

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns